ArticleAdvanced healthcare materials2016
Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection.
Article in Advanced healthcare materials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Application of bacteriophages in the prevention and control of bacterial infectious diseases in animals.Frontiers in microbiology · 2026Review
- A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Virus-like particle encapsulation of functional proteins: advances and applications.Theranostics · 2024Review
- Article
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- Phages in vaccine design and immunity; mechanisms and mysteries.Current opinion in biotechnology · 2021Review
- Phage display as a tool for vaccine and immunotherapy development.Bioengineering & translational medicine · 2020Review
- Enhancement of Photodynamic Cancer Therapy by Physical and Chemical Factors.Angewandte Chemie (International ed. in English) · 2019Review
- Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.Advanced drug delivery reviews · 2019Review
- Virus-Derived Peptides for Clinical Applications.Chemical reviews · 2017Review
- Phage-Enabled Nanomedicine: From Probes to Therapeutics in Precision Medicine.Angewandte Chemie (International ed. in English) · 2017Review
- Identification of Novel Short BaTiOACS applied materials & interfaces · 2016Article
- Novel nanoscale bacteriophage-based single-domain antibodies for the therapy of systemic infection caused by Candida albicans.Scientific reports · 2016Article
- Design, challenge, and promise of stimuli-responsive nanoantibiotics.Nano convergence · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Candida albicans (CA) is a kind of fungus that can cause high morbidity and mortality in immunocompromised patients. However, preventing CA infection in these patients is still a daunting challenge. Herein, inspired from the fact that immunization with secreted aspartyl proteinases 2 (Sap2) can prevent the infection, it is proposed to use filamentous phage, a human-safe virus nanofiber specifically infecting bacteria (≈900 nm long and 7 nm wide), to display an epitope peptide of Sap2 (EPS, with a sequence of Val-Lys-Tyr-Thr-Ser) on its side wall and thus serve as a vaccine for preventing CA infection. The engineered virus nanofibers and recombinant Sap2 (rSap2) are then separately used to immunize mice. The humoral and cellular immune responses in the immunized mice are evaluated. Surprisingly, the virus nanofibers significantly induce mice to produce strong immune response as rSap2 and generate antibodies that can bind Sap2 and CA to inhibit the CA infection. Consequently, immunization with the virus nanofibers in mice dramatically increases the survival rate of CA-infected mice. All these results, along with the fact that the virus nanofibers can be mass-produced by infecting bacteria cost-effectively, suggest that virus nanofibers displaying EPS can be a vaccine candidate against fungal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.